Diamyd Medical AB (publ) (STO:DMYD.B)
Sweden · Delayed Price · Currency is SEK 1.090
+0.020 (1.87%)
Jul 3, 2026, 5:29 PM CET
Diamyd Medical AB Income Statement
Financials in millions SEK. Fiscal year is September - August.
Millions SEK. Fiscal year is Sep - Aug.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | May '26 May 31, 2026 | Aug '25 Aug 31, 2025 | Aug '24 Aug 31, 2024 | Aug '23 Aug 31, 2023 | Aug '22 Aug 31, 2022 | Aug '21 Aug 31, 2021 |
| 0.43 | 0.13 | 0.13 | 0.55 | 0.45 | 0.25 | |
Revenue Growth (YoY) | 234.88% | - | -76.19% | 20.26% | 79.45% | -25.81% |
Cost of Revenue | 3.41 | 3.84 | 3.71 | 3.63 | 4.4 | 2.5 |
Gross Profit | -2.97 | -3.71 | -3.58 | -3.09 | -3.95 | -2.25 |
Selling, General & Admin | 68.67 | 56.55 | 44.79 | 39.7 | 31.93 | 25.63 |
Research & Development | 211.04 | 119.5 | 96.48 | 69.91 | 75.57 | 56.86 |
Other Operating Expenses | -2.17 | -3.03 | -3.16 | -1.72 | -0.89 | 0.55 |
Operating Expenses | 284.59 | 179.53 | 143.69 | 112.76 | 110.99 | 83.82 |
Operating Income | -287.57 | -183.23 | -147.27 | -115.85 | -114.94 | -86.07 |
Interest Expense | -1.53 | - | -0.01 | -0 | -0.25 | -0.45 |
Interest & Investment Income | 2.08 | 2.34 | 3.75 | 1.05 | 0.07 | 0 |
Earnings From Equity Investments | -1.26 | - | 6.12 | -4.96 | -3.24 | - |
Currency Exchange Gain (Loss) | 4.16 | 4.16 | 0.12 | 3.68 | 8.19 | 2.15 |
Other Non Operating Income (Expenses) | -0 | -0 | -0 | 0 | -0 | 0 |
EBT Excluding Unusual Items | -284.13 | -176.73 | -137.3 | -116.07 | -110.17 | -84.37 |
Gain (Loss) on Sale of Investments | 0.49 | 6.96 | -9.14 | - | 6.65 | 144.41 |
Asset Writedown | - | - | -5.41 | - | - | - |
Pretax Income | -283.65 | -169.78 | -151.85 | -116.07 | -103.52 | 60.05 |
Net Income | -283.65 | -169.78 | -151.85 | -116.07 | -103.52 | 60.05 |
Net Income to Common | -283.65 | -169.78 | -151.85 | -116.07 | -103.52 | 60.05 |
Net Income Growth | - | - | - | - | - | 518.46% |
Shares Outstanding (Basic) | 141 | 113 | 95 | 78 | 77 | 70 |
Shares Outstanding (Diluted) | 141 | 113 | 95 | 78 | 77 | 70 |
Shares Change (YoY) | 36.71% | 18.81% | 20.98% | 2.29% | 9.65% | 0.90% |
EPS (Basic) | -2.01 | -1.51 | -1.60 | -1.48 | -1.35 | 0.86 |
EPS (Diluted) | -2.01 | -1.51 | -1.60 | -1.48 | -1.35 | 0.86 |
EPS Growth | - | - | - | - | - | 512.92% |
Free Cash Flow | -194.03 | -179.73 | -137.21 | -122.4 | -127.87 | -113.69 |
Free Cash Flow Per Share | -1.38 | -1.60 | -1.45 | -1.56 | -1.67 | -1.63 |
Operating Margin | -66566.67% | -140949.23% | -113287.69% | -21217.22% | -25316.30% | -34020.55% |
Profit Margin | -65659.03% | -130597.69% | -116807.69% | -21258.79% | -22801.10% | 23733.60% |
Free Cash Flow Margin | -44913.19% | -138254.61% | -105543.08% | -22418.32% | -28165.42% | -44937.94% |
EBITDA | -280.63 | -176.73 | -141.69 | -110.98 | -110.55 | -85.29 |
D&A For EBITDA | 6.94 | 6.5 | 5.58 | 4.87 | 4.38 | 0.78 |
EBIT | -287.57 | -183.23 | -147.27 | -115.85 | -114.94 | -86.07 |
Revenue as Reported | 4.12 | 5.02 | 4.36 | 3.75 | 2.58 | 0.44 |